Feature | Thrombectomy Devices | June 12, 2015

Ultrasound to Breakup STEMI Causing Clots in Heart Attack Patients

Breakthrough research at ASE demonstrates contrast ultrasound may help restore some blood flow in myocardial infarction patients

STEMI, ultrasound to treat heart attacks, ultrasound to treat STEMI

June 12, 2015 - Researchers presented data at the 2015 American Society of Echocardiography (ASE) meeting in June showing intravenous microbubbles combined with transthoracic ultrasound can help restore blood flow to the heart muscle in acute ST-segment elevation myocardial infarction (STEMI), potentially preserving heart function in these patients.  This sonothrombolysis method uses ultrasound to burst ultrasound contrast bubbles inside the STEMI-causing clot, which creates micro-channels for blood flow within the clot.  

This method also may help reduce the "no-reflow"phenomena following percutaneous coronary intervention (PCI). This is believed to be caused by stenting sending clot emboli downstream into the capillaries. Using ultrasound as a therapy device also has advantages of imaging the anatomy simultaneously. 
 
Nearly 250,000 people experience STEMI heart attacks annually and one of the most important factors for recovery is quick treatment to reduce blockages and restore blood flow to prevent muscle death. While this sonothrombolysis technique has previously been studied in animals, this is the first study to test the method in humans.
 
"This is a breakthrough, first-in-humans study in patients with acute myocardial infarction that has the potential to revolutionize the treatment of these patients and other acute thrombotic diseases such as stroke and deep venous thrombosis," said senior author Wilson Mathias, Jr., M.D., University of Sí£o Paulo Medical School in Sí£o Paulo, Brazil.  
 
The research team used a standard diagnostic ultrasound transducer to apply high mechanical index impulses during a continuous infusion of Definity (produced by Lantheus) microbubble contrast agent in a large emergency room setting. The combination of ultrasound and echo contrast were used both immediately prior to and immediately following emergent PCI.  Those patients who were randomized to one of two sonothrombolysis groups showed both higher recanalization rates at initial angiography and improving cardiac function. Most importantly, no patient deaths were experienced and door-to-dilation times were not affected, demonstrating both safety and feasibility for this technique. 
 
Ultrasound contrast is composed of microscopic lipid spheres that are injected into the patient's bloodstream.  The bubbles return the ultrasonic sound waves used to form an image and enhance the blood.  The ultrasonic waves also shatter the bubbles and it is the physics of the cavitaion caused by breaking bubbles that enables the microscopic breakdown of the thrombus. 
 
Researchers on the study, "Safety and Feasibility of Diagnostic Ultrasound High Mechanical Index Impulses in Restoring Epicardial Flow in Acute ST Segment Elevation Myocardial Infarction in Humans," included Bruno Garcia Tavares, Jeane M. Tsutsui, Miguel Osmar Aguiar, Diego Garcia, Mucio T. Oliveira, Alexandre Soeiro, Jose C. Nicolau, Pedro Lemos, Roberto Kalil, and Wilson Mathias, Jr. of Heart Institute (InCor) - University of Sí£o Paulo Medical School in Sí£o Paulo, Brazil; and  Thomas R. Porter of the University of Nebraska Medical Center in Omaha.
 
In future technology sessions at ASE, there were discussions on developing new echo contrast agents with embedded lytic therapy in the lipid shell to deliver lyics only to the targeted anatomy.   
 
For more information: www.asescientificsessions.org
 

Related Content

People watch the presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., live in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long term surgical outcomes. #TCT2019

People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes. 

Feature | Cath Lab | October 03, 2019
October 3, 2019 – Five-year data from the EXCEL Trial showed patients with left main coronary disease treated with pe
Two Stents Implanted in Democratic Presidential Candidate Bernie Sanders, suffers chest pain
News | Cath Lab | October 02, 2019 | Dave Fornell, Editor
October 2, 2019 — Democratic presidential candidate Sen.
Bypass Surgery and Coronary Stenting Yield Comparable 10-Year Survival
News | Cath Lab | September 25, 2019
Ten-year survival rates are similar for bypass surgery and coronary stenting with drug-eluting stents in randomized...
Complete Revascularization Superior to Culprit Lesion-only Intervention
News | Cath Lab | September 10, 2019
An international randomized trial has shown that complete revascularization reduces major cardiovascular events...
The cath lab staff UH Portage Medical Center.

The cath lab staff UH Portage Medical Center.

Feature | Cath Lab | September 09, 2019 | Anjan Gupta, M.D., FACC, FSCAI
Primary percutaneous coronary intervention (PCI) is the preferred treatment for acute...
FDA Grants Shockwave Medical Breakthrough Status for Coronary Intravascular Lithotripsy
News | Cath Lab | September 03, 2019
Shockwave Medical Inc. has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA)...
Compound Could Help Improve Heart Attack Recovery
News | Cath Lab | August 27, 2019
Imagine there were a drug that you could take soon after a heart attack that could reduce damage by protecting healthy...
New Alliance Announced Between Transcatheter Cardiovascular Therapeutics and VEITHsymposium
News | Cath Lab | June 20, 2019
VEITHsymposium and the Cardiovascular Research Foundation (CRF) announced an alliance between Transcatheter...
Overlay Init